Citation

BibTex format

@article{Wild:2021:10.1136/bmjresp-2021-001049,
author = {Wild, JM and Porter, JC and Molyneaux, PL and George, PM and Stewart, I and Allen, RJ and Aul, R and Baillie, JK and Barratt, SL and Beirne, P and Bianchi, SM and Blaikley, JF and Brooke, J and Chaudhuri, N and Collier, G and Denneny, EK and Docherty, A and Fabbri, L and Gibbons, MA and Gleeson, F and Gooptu, B and Hall, IP and Hanley, NA and Heightman, M and Hillman, TE and Johnson, SR and Jones, MG and Khan, F and Lawson, R and Mehta, P and Mitchell, JA and Plate, M and Poinasamy, K and Quint, JK and Rivera-Ortega, P and Semple, M and Simpson, AJ and Smith, DJF and Spears, M and Spencer, LG and Stanel, SC and Thickett, DR and Thompson, AAR and Walsh, SLF and Weatherley, ND and Weeks, ME and Wootton, DG and Brightling, CE and Chambers, RC and Ho, L-P and Jacob, J and Piper, Hanley K and Wain, L and Jenkins, RG},
doi = {10.1136/bmjresp-2021-001049},
journal = {BMJ Open Respiratory Research},
pages = {1--10},
title = {Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)},
url = {http://dx.doi.org/10.1136/bmjresp-2021-001049},
volume = {8},
year = {2021}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD).Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment.Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals.Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.
AU - Wild,JM
AU - Porter,JC
AU - Molyneaux,PL
AU - George,PM
AU - Stewart,I
AU - Allen,RJ
AU - Aul,R
AU - Baillie,JK
AU - Barratt,SL
AU - Beirne,P
AU - Bianchi,SM
AU - Blaikley,JF
AU - Brooke,J
AU - Chaudhuri,N
AU - Collier,G
AU - Denneny,EK
AU - Docherty,A
AU - Fabbri,L
AU - Gibbons,MA
AU - Gleeson,F
AU - Gooptu,B
AU - Hall,IP
AU - Hanley,NA
AU - Heightman,M
AU - Hillman,TE
AU - Johnson,SR
AU - Jones,MG
AU - Khan,F
AU - Lawson,R
AU - Mehta,P
AU - Mitchell,JA
AU - Plate,M
AU - Poinasamy,K
AU - Quint,JK
AU - Rivera-Ortega,P
AU - Semple,M
AU - Simpson,AJ
AU - Smith,DJF
AU - Spears,M
AU - Spencer,LG
AU - Stanel,SC
AU - Thickett,DR
AU - Thompson,AAR
AU - Walsh,SLF
AU - Weatherley,ND
AU - Weeks,ME
AU - Wootton,DG
AU - Brightling,CE
AU - Chambers,RC
AU - Ho,L-P
AU - Jacob,J
AU - Piper,Hanley K
AU - Wain,L
AU - Jenkins,RG
DO - 10.1136/bmjresp-2021-001049
EP - 10
PY - 2021///
SN - 2052-4439
SP - 1
TI - Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
T2 - BMJ Open Respiratory Research
UR - http://dx.doi.org/10.1136/bmjresp-2021-001049
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000700187500002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://bmjopenrespres.bmj.com/content/8/1/e001049
UR - http://hdl.handle.net/10044/1/92187
VL - 8
ER -

Publications policy

All members of the Centre should be aware of and follow our MTW Research Publication Policy (PDF).

General enquiries


For any enquiries about the Margaret Turner Warwick Centre for Fibrosing Lung Disease, please contact:

admin.mtwc@imperial.ac.uk